Munich-based Hema.to, a digital MedTech company, has secured €3.6M in fresh funding led by LUMO Labs. The round also saw support from Bayern Kapital, several US angel investors, and existing investors including Elaia Partners, Heal Capital and HTGF.
Monika Steger, Managing Director of Bayern Kapital, adds, “The workload and pressure in clinical laboratories are high and for life-threatening diseases such as leukaemia or lymphoma, early and accurate diagnosis can make the difference between negative disease progression and life-saving, early intervention.”
Related: OrganOx completes $142m equity financing led by HealthQuest Capital
“With Hema.to’s AI-supported analysis platform, the time taken to analyse blood data can be reduced to a fraction of the usual manual time. In this way, the company not only relieves the burden on clinical laboratories and promotes patient well-being, but also addresses a global market with a volume of several billion dollars.”
“We therefore see great potential in Hema.to’s solution – both in Europe, where it is already being used in various laboratories and internationally.”
Bayern Kapital, the VC firm of the Free State of Bavaria, manages €700M and invests up to €25M per company. With over 110 active portfolio companies and 30 years of experience, it is one of the “strongest” investors in the DACH region. Since 1995, it has invested over €500M in 320+ startups.
With increasing sample volumes and staff shortages in Europe’s busiest clinical labs, cytometry teams face long processing times and a higher risk of missed diagnoses. Hema.to’s AI-powered cytometry technology reduces analysis time from 20 minutes to one minute, improving leukaemia and lymphoma detection while minimising false negatives.
As a deep tech AI company, Hema.to develops cloud-based clinical-grade software for early and precise diagnosis of blood cancers and immune diseases, supporting personalised treatment based on individual immune profiles.
Founded in 2021 by Dr. Karsten Miermans, Felix Kunzweiler, and Dr. Franz Elsner—later joined by Dr. Aleksandra Mezydlo—Hema.to has expanded into a team of 22 specialists across regulatory, medical, AI, engineering, and commercial domains.
Hema.to’s AI leverages a database of over 600,000 files from 20+ leading centres to support blood cancer diagnosis. Its CE-marked AI models are already in use across European labs and hospitals, with an end-to-end solution undergoing certification.
Beyond Europe, the company collaborates with top US institutes like U Penn and has a distribution partnership in Israel.
